证券代码：300741 证券简称：华宝股份 公告编号：2025-048 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《深 圳证券交易所创业板上市公司自律监管指南第 1 号——业务办理》（以下简称 "《监管指南》"）等相关规定，公司对 2025 年限制性股票激励计划（以下简 称"本次激励计划"）拟授予的激励对象名单在公司内部进行了公示。公司监事 会结合公示情况对拟激励对象进行了审核，相关公示及核查情况如下： 一、公示情况及核查方式 本公司及监事会全体成员保证公告内容不存在虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 华宝香精股份有限公司（以下简称"公司"）于 2025 年 8 月 25 日召开第三 届董事会第二十次会议、第三届监事会第十四次会议，审议通过了《关于<华宝 香精股份有限公司 2025 年限制性股票激励计划（草案）>及其摘要的议案》等相 关议案，具体内容详见公司分别于 2025 年 8 月 26 日刊登在巨潮资讯网 （www.cninfo.com.cn）的相关公告。 华宝香精股份有限公司 监事会关于 2025 年限制性股票激励计划首次授予 ...

（文章来源：证券日报） 证券日报网讯华宝股份11月19日在互动平台回答投资者提问时表示，公司定期报告中披露的主要客户 （品牌）均真实存在，未来公司仍将严格按照监管要求及时履行信息披露义务。 ...

（记者 胡玲） 华宝股份（300741.SZ）11月19日在投资者互动平台表示，公司未投资相关银行和证券公司，具体内容 请以公司定期报告披露为准。 每经AI快讯，有投资者在投资者互动平台提问：贵公司投资了哪些银行和证券公司？ ...

（编辑 袁冠琳） 证券日报网讯 华宝股份11月12日在互动平台回答投资者提问时表示，股价的波动受多重因素的影响， 敬请投资者注意投资风险。公司目前不存在应披露而未披露的重大事项。未来公司将严格按照监管要求 及时履行信息披露义务。 ...

Core Viewpoint - Huabao Co., Ltd. has publicly committed to avoiding competition with its controlling shareholder, ensuring independent operation and compliance with relevant laws and regulations [1] Group 1 - The controlling shareholder has made a public commitment regarding the avoidance of competition, as detailed in the company's IPO prospectus [1] - The company and its controlling shareholder will continue to strictly adhere to this commitment and relevant legal regulations [1] - A corporate governance supervision mechanism has been established to institutionalize the management of related transactions and controlling shareholder behaviors, safeguarding the legal rights of all shareholders [1] Group 2 - The company will fulfill its information disclosure obligations in a timely manner in accordance with regulatory requirements if any significant matters arise in the future [1]

Core Viewpoint - The company, Huabao Co., Ltd. (300741), is committed to closely monitoring changes in policies and market environments while actively advancing its strategic planning and business expansion [1] Business Strategy - The company focuses on strengthening its industrial chain and upgrading core capabilities, emphasizing the integration of industrial resources through mergers and acquisitions [1] - There is a strong potential for development in the fields of food ingredients and daily chemical fragrances, which the company aims to fully leverage [1] - The company will continue to optimize its operational strategy to enhance overall corporate value [1] Compliance and Disclosure - The company will strictly adhere to regulatory requirements regarding information disclosure, especially in matters related to mergers and acquisitions [1]

Group 1 - The artificial meat concept stocks experienced a short-term surge, with Guoen Co., Ltd. hitting the daily limit up [1] - Fuxiang Pharmaceutical saw an increase of over 15% [1] - Other companies such as Huabao Co., Haoxiangni, Shuanghui Development, Chengzhi Co., and Chunxue Food also experienced gains [1]

Group 1 - Yinghuate will distribute a cash dividend of 0.8 yuan (including tax) for every 10 shares, with the record date on November 13, 2025, and the ex-dividend date on November 14, 2025 [1] - Maihe will distribute a cash dividend of 0.7 yuan (including tax) for every 10 shares, with the record date on November 12, 2025, and the ex-dividend date on November 13, 2025 [1] - Yueda Investment will distribute a cash dividend of 0.03 yuan (including tax) per share, with the record date on November 12, 2025, and the ex-dividend date on November 13, 2025 [1] Group 2 - Huabao will distribute a cash dividend of 0.5 yuan (including tax) for every 10 shares, with the record date on November 12, 2025, and the ex-dividend date on November 13, 2025 [2]

证券日报网讯 11月6日晚间，华宝股份发布2025年第三季度权益分派实施公告称，公司2025年第三季度 权益分派方案为每10股派0.5元人民币现金（含税），股权登记日为2025年11月12日，除权除息日为 2025年11月13日。 （文章来源：证券日报） ...

Core Viewpoint - The company emphasizes its commitment to independent innovation and has a significant number of patents, which reflects its ongoing research and development efforts [1] Patent and R&D Summary - As of June 30, 2025, the company holds a total of 316 patents, including 176 invention patents, 134 utility model patents, and 6 design patents [1] - The company acknowledges that the patent application process involves certain time delays, which may not immediately reflect the outcomes of its R&D efforts [1] - For core technologies that are not suitable for public patent applications, the company employs trade secrets and has established strict internal management and confidentiality mechanisms [1] R&D Mechanisms - The company has developed a comprehensive mechanism for project initiation and the transformation of research results, which continuously promotes the output and industrial application of R&D achievements [1] - The company adheres to accounting standards and information disclosure regulations, ensuring that detailed information regarding patent numbers and R&D expenditures is available in its periodic reports [1]